All In Biotech

Drug Trial Radar · NCT02065375

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

A Multicenter, Randomized, Dose-Ranging, Double-Masked, Placebo-Controlled Phase 2 Study Evaluating the Safety and Efficacy of RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 109 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

109

Actual

Start

Feb 28, 2014

Primary completion

Sep 30, 2014

Study completion Sep 30, 2014

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
AbbVie
First posted
Feb 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.

Conditions

  • Inflammation and Pain Following Ocular Surgery

Interventions

  • Omaveloxolone Ophthalmic Suspension 1.0%Drug

  • Omaveloxolone Opthalmic Suspension 0.5%Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absence of Anterior Chamber Cells at Day 15 (Visit 5)Time frame: 15 days after the participant receives the first dose
  2. Absence of Ocular Pain at Day 4 (Visit 3)Time frame: 4 days after the participant receives the first dose

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Garden Grove, California

  • Site not named

    Fort Myers, Florida

  • Site not named

    Kansas City, Missouri

  • Site not named

    Elizabeth City, North Carolina

  • Site not named

    Austin, Texas

  • Site not named

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.